Glycolytic Plasticity of Metastatic Lung Cancer Captured by Noninvasive 18F-FDG PET/CT and Serum 1H-NMR Analysis: An Orthotopic Murine Model Study

We aim to establish a noninvasive diagnostic platform to capture early phenotypic transformation for metastasis using 18F-FDG PET and 1H-NMR-based serum metabolomics. Mice with implantation of NCI-H460 cells grew only primary lung tumors in the localized group and had both primary and metastatic lung tumors in the metastatic group. The serum metabolites were analyzed using 1H-NMR at the time of PET/CT scan. The glycolysis status and cell proliferation were validated by Western blotting and staining. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic accuracy of SUVmean and serum metabolites in metastasis. In the metastatic mice, the SUVmean of metastatic tumors was significantly higher than that of primary lung tumors in PET images, which was supported by elevated glycolytic protein expression of HK2 and PKM2. The serum pyruvate level in the metastatic group was significantly lower than that in the localized group, corresponding to increased pyruvate-catalyzed enzyme and proliferation rates in metastatic tumors. In diagnosing localized or metastatic tumors, the areas under the ROC curves of SUVmean and pyruvate were 0.92 and 0.91, respectively, with p < 0.05. In conclusion, the combination of 18F-FDG PET and 1H-NMR-based serum metabolomics demonstrated the feasibility of a glycolytic platform for diagnosing metastatic lung cancers.

[1]  Zihan Zang,et al.  Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer , 2022, Frontiers in Oncology.

[2]  D. Jacob,et al.  Development, Validation, and Use of 1H-NMR Spectroscopy for Evaluating the Quality of Acerola-Based Food Supplements and Quantifying Ascorbic Acid , 2022, Molecules.

[3]  Yaming Li,et al.  18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer. , 2022, Clinical lung cancer.

[4]  T. Andreassen,et al.  Identifying metabolic alterations in newly diagnosed small cell lung cancer patients , 2021, Metabolism open.

[5]  L. Dubois,et al.  Mass spectrometry imaging of L-[ring-13C6]-labeled phenylalanine and tyrosine kinetics in non-small cell lung carcinoma , 2021, Cancer & metabolism.

[6]  Michael K. Wendt,et al.  Pyruvate carboxylase and cancer progression , 2021, Cancer & metabolism.

[7]  T. Yen,et al.  Radiation-Induced Metabolic Shifts in the Hepatic Parenchyma: Findings from 18F-FDG PET Imaging and Tissue NMR Metabolomics in a Mouse Model for Hepatocellular Carcinoma , 2020, Molecules.

[8]  Xu Zhang,et al.  Combining 18F‐FDG PET/CT and Serum Lactate Dehydrogenase for Prognostic Evaluation of Small Cell Lung Cancer , 2020, Frontiers in Pharmacology.

[9]  Jun Yu,et al.  Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications , 2020, Oncogene.

[10]  Joram M. Posma,et al.  Identifying unknown metabolites using NMR-based metabolic profiling techniques , 2020, Nature Protocols.

[11]  S. Sizemore,et al.  Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells. , 2020, Journal of visualized experiments : JoVE.

[12]  C. Schofield,et al.  Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells , 2020, Communications Biology.

[13]  D. Maintz,et al.  Monitoring treatment effects in lung cancer-bearing mice: clinical CT and clinical MRI compared to micro-CT , 2020, European Radiology Experimental.

[14]  A. Koromilas,et al.  Detection of Lung Tumor Progression in Mice by Ultrasound Imaging. , 2020, Journal of visualized experiments : JoVE.

[15]  Yan Fu,et al.  Secreted Pyruvate Kinase M2 Promotes Lung Cancer Metastasis through Activating the Integrin Beta1/FAK Signaling Pathway. , 2020, Cell reports.

[16]  T. Yen,et al.  Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  D. Raftery,et al.  Analysis of Plasma, Serum, and Whole Blood Metabolites Using 1H NMR Spectroscopy. , 2019, Methods in molecular biology.

[18]  J. Mansfield,et al.  Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer , 2018, Journal of visualized experiments : JoVE.

[19]  M. Halse,et al.  SABRE hyperpolarization enables high-sensitivity 1H and 13C benchtop NMR spectroscopy† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8an00596f , 2018, The Analyst.

[20]  Huang Sun,et al.  Serum proton NMR metabolomics analysis of human lung cancer following microwave ablation , 2018, Radiation oncology.

[21]  M. Halse,et al.  SABRE hyperpolarization enables high-sensitivity 1H and 13C benchtop NMR spectroscopy , 2018, The Analyst.

[22]  B. Greenspan.  Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging. , 2017, Translational lung cancer research.

[23]  Joerg M. Buescher,et al.  Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. , 2016, Cell reports.

[24]  Grey Giddins,et al.  Statistics , 2016, The Journal of hand surgery, European volume.

[25]  T. Bathen,et al.  Identification of Metastasis-Associated Metabolic Profiles of Tumors by 1H-HR-MAS-MRS123 , 2015, Neoplasia.

[26]  F. Demirağ,et al.  The Evaluation of FDG PET/CT Scan Findings in Patients with Organizing Pneumonia Mimicking Lung Cancer , 2015, Molecular imaging and radionuclide therapy.

[27]  V. Rangarajan,et al.  Imaging of lung cancer: Implications on staging and management , 2015, Indian Journal of Radiology and Imaging.

[28]  A. Nomoto,et al.  New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice , 2015, Cancer science.

[29]  Ido D. Weiss,et al.  In the Hunt for Therapeutic Targets: Mimicking the Growth, Metastasis, and Stromal Associations of Early-Stage Lung Cancer Using a Novel Orthotopic Animal Model , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  Melissa L McPheeters,et al.  Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. , 2014, JAMA.

[31]  M. Desco,et al.  Comparison of Methods to Reduce Myocardial 18F-FDG Uptake in Mice: Calcium Channel Blockers versus High-Fat Diets , 2014, PloS one.

[32]  M. Spraul,et al.  Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. , 2014, Analytical chemistry.

[33]  H. Al-Jahdali,et al.  Guidelines for the role of FDG-PET/CT in lung cancer management. , 2012, Journal of infection and public health.

[34]  F. Rumjanek,et al.  Energy Metabolism in H460 Lung Cancer Cells: Effects of Histone Deacetylase Inhibitors , 2011, PloS one.

[35]  R. Bamezai,et al.  Human pyruvate kinase M2: A multifunctional protein , 2010, Protein science : a publication of the Protein Society.

[36]  David S. Wishart,et al.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation , 2009, Nucleic Acids Res..

[37]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[38]  T. Ebbels,et al.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.

[39]  D. Mankoff,et al.  Monitoring Targeted Therapy: Is Fluorodeoxylucose Uptake a Marker of Early Response? , 2006, Clinical Cancer Research.

[40]  C. Kent.  Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. , 2005, Biochimica et biophysica acta.